Details for Patent: 11,603,363

Which drugs does patent 11,603,363 protect, and when does it expire?

Patent 11,603,363 protects FABHALTA and is included in one NDA.

This patent has twenty patent family members in nine countries.

Summary for Patent: 11,603,363

Title:	Crystalline form of LNP023
Abstract:	Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
Inventor(s):	Zichen JIA, Philipp Lustenberger, Marie Meyer, Massimo Moratto
Assignee:	Novartis AG
Application Number:	US17/322,409
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Dosage form;

Drugs Protected by US Patent 11,603,363

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes			Y	Y

International Family Members for US Patent 11,603,363

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2021276912
Australia	2024201640
Canada	3180829
China	115667240